Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products ... menopausal hormone replacement, and human growth hormone. Besides Ozempic and Wegovy, the company has made ...

Novo Nordisk has started building ... up 3% on the same period of 2023 - but Novo Nordisk has a stated ambition of generating a "sustained growth outlook" for the business as sales of some ...

and growth hormone deficiency. Sales of this franchise amounted to about DKK 5.71 billion in Q4 2024 [8.7% of Novo Nordisk's total revenue], an increase of 24.8% year-on-year and 24.7% quarter-on ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

Learn more about whether Corcept Therapeutics Incorporated or Novo Nordisk A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.